Pfizer Canada and BioNTech Receive Health Canada Approval of Omicron KP.2 Variant Adapted COVID-19 Vaccine [Yahoo! Finance]
BioNTech SE - American Depositary Shares (BNTX)
Company Research
Source: Yahoo! Finance
It is expected to be available in Canada in the coming weeks. The updated COVID-19 vaccine is tailored to the KP.2 strain of the SARS-CoV-2 Omicron JN.1 lineage. KIRKLAND, QC Sept. 24, 2024 /CNW/ - Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced today that Health Canada has authorized the KP.2 variant adapted COMIRNATY ® COVID-19 vaccine for ages 6 months and older. The updated COMIRNATY ® vaccine targets the Omicron KP.2 variant, one of the most recently circulating SARS-CoV-2 lineages. The adapted COVID-19 vaccine will be available in Canada as a single dose for individuals 5 years of age and older, regardless of prior COVID-19 vaccination history. For children 6 months through 4 years of age, COMIRNATY ® is authorized for administration as a three-dose series in those without a history of completion of a COVID-19 primary vaccination course, or as a single dose for those with a history of completion of a COVID-19 primary vaccination course. The newly f
Show less
Read more
Impact Snapshot
Event Time:
BNTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BNTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BNTX alerts
High impacting BioNTech SE - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BNTX
News
- BioNTech SE (NASDAQ: BNTX) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating. They now have a $145.00 price target on the stock, up previously from $93.00.MarketBeat
- Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union [Yahoo! Finance]Yahoo! Finance
- Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European UnionGlobeNewswire
- BioNTech SE (NASDAQ: BNTX) had its price target raised by analysts at Deutsche Bank Aktiengesellschaft from $95.00 to $150.00. They now have a "buy" rating on the stock.MarketBeat
- BioNTech SE (NASDAQ: BNTX) had its price target raised by analysts at UBS Group AG from $97.00 to $131.00. They now have a "neutral" rating on the stock.MarketBeat
BNTX
Earnings
- 8/5/24 - Miss
BNTX
Sec Filings
- 9/27/24 - Form 144
- 9/25/24 - Form 144
- 9/20/24 - Form 6-K
- BNTX's page on the SEC website